PE20121816A1 - Combinaciones de un inhibidor de pi3k y un inhibidor de mek - Google Patents

Combinaciones de un inhibidor de pi3k y un inhibidor de mek

Info

Publication number
PE20121816A1
PE20121816A1 PE2012000470A PE2012000470A PE20121816A1 PE 20121816 A1 PE20121816 A1 PE 20121816A1 PE 2012000470 A PE2012000470 A PE 2012000470A PE 2012000470 A PE2012000470 A PE 2012000470A PE 20121816 A1 PE20121816 A1 PE 20121816A1
Authority
PE
Peru
Prior art keywords
inhibitor
methyl
mek
combinations
gdc
Prior art date
Application number
PE2012000470A
Other languages
English (en)
Spanish (es)
Inventor
Marcia Belvin
Iris T Chan
Lori Friedman
Klaus P Hoeflich
John Prescott
Jeffrey Wallin
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43072663&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20121816(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20121816A1 publication Critical patent/PE20121816A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
PE2012000470A 2009-10-12 2010-10-11 Combinaciones de un inhibidor de pi3k y un inhibidor de mek PE20121816A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25085209P 2009-10-12 2009-10-12

Publications (1)

Publication Number Publication Date
PE20121816A1 true PE20121816A1 (es) 2013-01-02

Family

ID=43072663

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2012000470A PE20121816A1 (es) 2009-10-12 2010-10-11 Combinaciones de un inhibidor de pi3k y un inhibidor de mek

Country Status (24)

Country Link
US (1) US20110086837A1 (enExample)
EP (1) EP2488178B1 (enExample)
JP (2) JP2013507415A (enExample)
KR (1) KR101489045B1 (enExample)
CN (1) CN102740851B (enExample)
AR (1) AR078588A1 (enExample)
AU (1) AU2010314287A1 (enExample)
BR (1) BR112012008483A2 (enExample)
CA (1) CA2776944A1 (enExample)
CL (1) CL2012000913A1 (enExample)
CO (1) CO6531463A2 (enExample)
CR (1) CR20120173A (enExample)
EC (1) ECSP12011865A (enExample)
ES (1) ES2609767T3 (enExample)
IL (1) IL219105A0 (enExample)
MA (1) MA33974B1 (enExample)
MX (1) MX345155B (enExample)
NZ (1) NZ599939A (enExample)
PE (1) PE20121816A1 (enExample)
PH (1) PH12012500709A1 (enExample)
RU (1) RU2563193C2 (enExample)
TW (1) TWI428336B (enExample)
WO (1) WO2011054620A1 (enExample)
ZA (1) ZA201202618B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011000440A (es) 2008-07-11 2011-02-24 Novartis Ag Combinacion de (a) un inhibidor de fosfoinositido 3-cinasa y (b) un modulador de la ruta de ras/raf/mek.
EA024252B1 (ru) 2009-01-08 2016-08-31 Кьюрис, Инк. Ингибиторы фосфоинозитид-3-киназ с цинксвязывающей группой
PH12012501361A1 (en) 2009-12-31 2012-10-22 Centro Nac De Investigaciones Oncologicas Cnio Tricyclic compounds for use as kinase inhibitors
WO2012098387A1 (en) 2011-01-18 2012-07-26 Centro Nacional De Investigaciones Oncológicas (Cnio) 6, 7-ring-fused triazolo [4, 3 - b] pyridazine derivatives as pim inhibitors
CA2830822C (en) 2011-04-01 2018-10-02 Curis, Inc. A thienopyrimidine phosphoinositide 3-kinase inhibitor with a zinc binding moiety
AR087405A1 (es) 2011-08-01 2014-03-19 Genentech Inc Metodos para tratar el cancer por el uso de antagonistas de union al eje pd-1 e inhibidores de mek
US9675595B2 (en) 2011-08-31 2017-06-13 Novartis Ag Synergistic combinations of PI3K- and MEK-inhibitors
CN103957902A (zh) 2011-10-13 2014-07-30 基因泰克公司 药理学诱导的胃酸过少的治疗
EP2776051A4 (en) * 2011-10-28 2015-06-17 Hoffmann La Roche THERAPEUTIC COMBINATIONS AND METHOD FOR THE TREATMENT OF MELANOMA
WO2013082511A1 (en) 2011-12-02 2013-06-06 Genentech, Inc. Methods for overcoming tumor resistance to vegf antagonists
PE20142020A1 (es) * 2012-04-06 2014-12-24 Sanofi Sa Metodos para tratar el cancer usando inhibidor de pi3k e inhibidor de mek
JP6093757B2 (ja) * 2012-04-19 2017-03-08 国立大学法人九州大学 医薬組成物
US9107926B2 (en) 2012-06-08 2015-08-18 Genentech, Inc. Mutant selectivity and combinations of a phosphoinositide 3-kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer
EP2879708A4 (en) 2012-08-02 2016-03-16 Genentech Inc ANTIBODY AND ANTI-ETBR IMMUNOCONJUGATES
US9463251B2 (en) 2012-08-02 2016-10-11 Genentech, Inc. Anti-ETBR antibodies and immunoconjugates
RS59113B1 (sr) * 2012-08-17 2019-09-30 Hoffmann La Roche Kombinovane terapije za melanom koje uključuju davanje kobimetiniba i vemurafiniba
SG11201507477XA (en) * 2013-03-14 2015-10-29 Genentech Inc Combinations of a mek inhibitor compound with an her3/egfr inhibitor compound and methods of use
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
ES2779975T3 (es) 2014-02-07 2020-08-21 Verastem Inc Métodos y composiciones para tratar el crecimiento celular anormal
SG10202007111TA (en) 2014-07-15 2020-09-29 Genentech Inc Compositions for treating cancer using pd-1 axis binding antagonists and mek inhibitors
WO2016040806A1 (en) * 2014-09-11 2016-03-17 The Regents Of The University Of California mTORC1 INHIBITORS
ES3014591T3 (en) 2018-09-11 2025-04-23 Curis Inc Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
CN110420330B (zh) * 2019-07-19 2020-05-29 南京医科大学 一种pi3k与mth1靶向药组合物的制药用途
JP2022547358A (ja) 2019-09-13 2022-11-14 ジ インスティテュート オブ キャンサー リサーチ：ロイヤル キャンサー ホスピタル 治療組成物、組み合わせ、及び使用方法
US11873296B2 (en) 2022-06-07 2024-01-16 Verastem, Inc. Solid forms of a dual RAF/MEK inhibitor

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1470356A1 (de) * 1964-01-15 1970-04-30 Thomae Gmbh Dr K Neue Thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung
BE754606A (fr) * 1969-08-08 1971-02-08 Thomae Gmbh Dr K Nouvelles 2-aminoalcoylamino-thieno(3,2-d)pyrimidines et leurs procedesde fabrication
BE759493A (fr) * 1969-11-26 1971-05-25 Thomae Gmbh Dr K Nouvelles 2-(5-nitro-2-furyl)-thieno(3,2-d) pyrimidines et procedes pour les fabriquer
US3763156A (en) * 1970-01-28 1973-10-02 Boehringer Sohn Ingelheim 2-heterocyclic amino-4-morpholinothieno(3,2-d)pyrimidines
CH592668A5 (enExample) * 1973-10-02 1977-10-31 Delalande Sa
GB1570494A (en) * 1975-11-28 1980-07-02 Ici Ltd Thienopyrimidine derivatives and their use as pesticides
US4510139A (en) * 1984-01-06 1985-04-09 Sterling Drug Inc. Substituted aminobenzamides and their use as agents which inhibit lipoxygenase activity
WO1995026956A1 (en) * 1994-04-01 1995-10-12 Shionogi & Co., Ltd. Oxime derivative and bactericide containing the same as active ingredient
US6974878B2 (en) * 2001-03-21 2005-12-13 Symyx Technologies, Inc. Catalyst ligands, catalytic metal complexes and processes using same
US6608053B2 (en) * 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
US7498304B2 (en) * 2000-06-16 2009-03-03 Curis, Inc. Angiogenesis-modulating compositions and uses
EE05450B1 (et) * 2000-07-19 2011-08-15 Warner-Lambert Company 4-jodofenlaminobenshdroksaamhapete oksgeenitud estrid, nende kristallvormid ja farmatseutilised kompositsioonid ning kasutamine
US7235537B2 (en) * 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
EP1606283B1 (en) * 2003-03-03 2008-10-08 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
US20050049276A1 (en) * 2003-07-23 2005-03-03 Warner-Lambert Company, Llc Imidazopyridines and triazolopyridines
US7538120B2 (en) * 2003-09-03 2009-05-26 Array Biopharma Inc. Method of treating inflammatory diseases
US7144907B2 (en) * 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
EP1674452A4 (en) * 2003-09-19 2007-10-10 Chugai Pharmaceutical Co Ltd NOVEL 4-PHENYLAMINO-BENZALDOXIME DERIVATIVE AND ITS USE AS MEK INHIBITOR
US7517994B2 (en) * 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
HRP20110498T1 (hr) * 2005-10-07 2011-08-31 Exelixis Azetidini kao inhibitori mek za liječenje proliferativnih bolesti
BRPI0710874A2 (pt) * 2006-04-26 2012-02-14 Hoffmann La Roche compostos de tienopirimidina, processos de produção dos referidos compostos, composições farmacêuticas contendo os mesmos, kit, produto, e usos dos compostos
WO2008021389A2 (en) * 2006-08-16 2008-02-21 Exelixis, Inc. Using pi3k and mek modulators in treatments of cancer
AU2007329352B2 (en) * 2006-12-07 2013-01-17 F. Hoffmann-La Roche Ag Phosphoinositide 3-kinase inhibitor compounds and methods of use
EP2205242B1 (en) * 2007-09-12 2015-04-15 Genentech, Inc. Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
CN103841976A (zh) * 2011-04-01 2014-06-04 基因泰克公司 Akt和mek抑制剂化合物的组合及其使用方法

Also Published As

Publication number Publication date
CO6531463A2 (es) 2012-09-28
US20110086837A1 (en) 2011-04-14
CR20120173A (es) 2012-07-04
WO2011054620A1 (en) 2011-05-12
HK1175125A1 (en) 2013-06-28
EP2488178A1 (en) 2012-08-22
AU2010314287A1 (en) 2012-05-03
JP2015038110A (ja) 2015-02-26
RU2012118974A (ru) 2013-11-20
NZ599939A (en) 2014-02-28
IL219105A0 (en) 2012-06-28
CL2012000913A1 (es) 2012-09-14
CN102740851B (zh) 2013-12-18
ES2609767T3 (es) 2017-04-24
PH12012500709A1 (en) 2012-10-29
KR101489045B1 (ko) 2015-02-02
JP2013507415A (ja) 2013-03-04
AU2010314287A2 (en) 2012-07-12
TWI428336B (zh) 2014-03-01
JP5745678B2 (ja) 2015-07-08
EP2488178B1 (en) 2016-11-16
MX345155B (es) 2017-01-18
AR078588A1 (es) 2011-11-16
BR112012008483A2 (pt) 2019-09-24
ZA201202618B (en) 2014-10-29
ECSP12011865A (es) 2012-06-29
MX2012004286A (es) 2012-05-22
RU2563193C2 (ru) 2015-09-20
CN102740851A (zh) 2012-10-17
CA2776944A1 (en) 2011-05-12
MA33974B1 (fr) 2013-02-01
TW201118082A (en) 2011-06-01
KR20120064132A (ko) 2012-06-18

Similar Documents

Publication Publication Date Title
PE20121816A1 (es) Combinaciones de un inhibidor de pi3k y un inhibidor de mek
EA201100971A1 (ru) Производные пиримидининдола для лечения злокачественного новообразования
RU2014120792A (ru) Способ лечения стромальных опухолей желудочно-кишечного тракта
EA201490194A1 (ru) Комбинированная терапия, включающая ингибитор cdk4/6 и ингибитор pi3k для применения в лечении рака
GEP20166455B (en) Methods of administering pirfenidone therapy
NI201000002A (es) Derivados de morfolino pirimidina utilizados en enfermedades relacionadas con mtor quinasa y/o p13k.
NI201500012A (es) Mã‰todos de tratamiento de cãncer usando 3 - ( 4 - (( 4 - ( morfolinometil ) bencil ) oxi ) - 1 - oxoisoindolin - 2 - il ) - 2, 6 - diona.
UA115131C2 (uk) Сполуки боронатного ефіру і його фармацевтичні рецептури
MX2020004023A (es) Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
UA115786C2 (uk) ФАРМАЦЕВТИЧНА КОМБІНАЦІЯ, ЩО МІСТИТЬ ІНГІБІТОР B-Raf, ІНГІБІТОР EGFR ТА, НЕОБОВ'ЯЗКОВО, ІНГІБІТОР РІ3K-?
EA201170940A1 (ru) Лечение рака с использованием комбинации бендамустина и анти-cd20-антитела
MX2012010226A (es) Uso de inhibidores de erbb3 en el tratamiento de canceres de mama triple negativos y de tipo basal.
CO6300964A2 (es) Una composicion farmaceutica que comprende una combinacion de un agente quimioterapeutico y un anticuerpo 3 antiglipicano
MX2012003175A (es) Regimen de dosificacion para administrar un anticuerpo bi-especifico epcamxcd3.
NZ600310A (en) 4-[2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine salts
MX2019003733A (es) Tratamiento de cancer de prostata.
RU2014112198A (ru) Синергические композиции ингибиторов pi3k и мек
BR112015030578A2 (pt) combinações farmacêuticas
ATE531721T1 (de) Cyanoaminochinolone als gsk-3-inhibitoren
MX347927B (es) Vitamina c y vitamina k libre de cromo, y composiciones de estas para tratar un estado o enfermedad en las que interviene nfkb.
CY1120375T1 (el) Υποκατεστημενο 1η-πυραζολο-5-ολικο νατριο
PH12013501163A1 (en) Compositions comprising a p13k inhibitor and a mek inhibitor and their use for treating cancer
WO2012145575A3 (en) Therapy for leukemia
SE0300098D0 (sv) Use of cyclin D1 inhibitors
ATE361746T1 (de) Botanischer extrakt mit antikrebs-aktivität enthaltend isoliquiritigenin

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed